177 related articles for article (PubMed ID: 27780639)
21. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
22. Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis.
Bai Z; Cai L; Umemoto E; Takeda A; Tohya K; Komai Y; Veeraveedu PT; Hata E; Sugiura Y; Kubo A; Suematsu M; Hayasaka H; Okudaira S; Aoki J; Tanaka T; Albers HM; Ovaa H; Miyasaka M
J Immunol; 2013 Mar; 190(5):2036-48. PubMed ID: 23365076
[TBL] [Abstract][Full Text] [Related]
23. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
25. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
26. [Function and biological activities of the autotaxin-LPA axis].
Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
[TBL] [Abstract][Full Text] [Related]
27. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
[TBL] [Abstract][Full Text] [Related]
29. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
30. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
31. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
32. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
33. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
[TBL] [Abstract][Full Text] [Related]
34. Linking the Autotaxin-LPA Axis to Medicinal Cannabis and the Endocannabinoid System.
Eymery MC; Boumendjel A; McCarthy AA; Hausmann J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542186
[TBL] [Abstract][Full Text] [Related]
35. Structural basis of substrate discrimination and integrin binding by autotaxin.
Hausmann J; Kamtekar S; Christodoulou E; Day JE; Wu T; Fulkerson Z; Albers HM; van Meeteren LA; Houben AJ; van Zeijl L; Jansen S; Andries M; Hall T; Pegg LE; Benson TE; Kasiem M; Harlos K; Kooi CW; Smyth SS; Ovaa H; Bollen M; Morris AJ; Moolenaar WH; Perrakis A
Nat Struct Mol Biol; 2011 Feb; 18(2):198-204. PubMed ID: 21240271
[TBL] [Abstract][Full Text] [Related]
36. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
37. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
40. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
